Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Frequently asked questions
What sector does Elicio Therapeutics Inc. (ELTX) operate in?
Elicio Therapeutics Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Elicio Therapeutics Inc. (ELTX) current stock price?
As of the latest data, Elicio Therapeutics Inc. stock price is $3.11, with a previous close of $3.02. Elicio Therapeutics Inc. gained $0.09 in the last trading session, representing a 2.98% increase.
What is Elicio Therapeutics Inc. (ELTX) current market capitalization?
Elicio Therapeutics Inc. market cap is approximately 81.74 million.
What is Elicio Therapeutics Inc. (ELTX) Earnings Per Share (EPS)?
The trailing EPS is -$2.30, and the forward EPS is -$2.43.
What is Elicio Therapeutics Inc. (ELTX) EBITDA?
Elicio Therapeutics Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -12.91 million.
Does Elicio Therapeutics Inc. (ELTX) pay dividends?
No. Elicio Therapeutics Inc. does not pay a dividend.
What is Elicio Therapeutics Inc. (ELTX) beta (volatility) score?
Elicio Therapeutics Inc. has a beta of 1.877, suggesting it is more volatile than the market.
